Literature DB >> 9630897

Virosomes: cationic liposomes enhance retroviral transduction.

C P Hodgson1, F Solaiman.   

Abstract

Retrovirus-derived vectors are overwhelmingly preferred over other methods for ex vivo gene therapy because they provide permanent integration of foreign genes into cellular DNA. In comparison, cationic lipids mediate efficent gene transfer, but expression is transient. When we combined cationic lipids with retrovirus particles we obtained a significant enhancement of transduction efficiency, depending upon the type of lipid formulation and the dose used. The relative effectiveness of these cytofectins was: DOSPA:DOPE > DOTMA:DOPE > DOTAP, resulting in 60-, 37-, and 5-fold increases in transduction efficiency, respectively, at optimum dosage. The effect of polycationic DOSPA:DOPE was dependent upon the viral envelope glycoprotein, was attainable by lipid treatment of either cells or virus particles, was not enhanced by the addition of polybrene, and was inhibited by chloroquine. These results strongly suggested that DOSPA:DOPE act primarily by modulation of charge associated with the viral envelope and cell membrane, enhancing retroviral transduction, rather than by providing an alternative pathway of transfection. DOSPA:DOPE is useful for improving the efficiency of gene transfer as well as the sensitivity with which retroviruses can be detected in biological fluids.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9630897     DOI: 10.1038/nbt0396-339

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN: 1087-0156            Impact factor:   54.908


  19 in total

1.  Isolation, immortalization, and initial characterization of uterine cell lines: an in vitro model system for the porcine uterus.

Authors:  G Wang; G A Johnson; T E Spencer; F W Bazer
Journal:  In Vitro Cell Dev Biol Anim       Date:  2000 Nov-Dec       Impact factor: 2.416

Review 2.  Gene delivery into primary T cells: overview and characterization of a transgenic model for efficient adenoviral transduction.

Authors:  Vincent Hurez; Robin D Hautton; James Oliver; R James Matthews; Casey K Weaver
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

3.  Optimization of the transductional efficiency of lentiviral vectors: effect of sera and polycations.

Authors:  Warren Denning; Suvendu Das; Siqi Guo; Jun Xu; John C Kappes; Zdenek Hel
Journal:  Mol Biotechnol       Date:  2013-03       Impact factor: 2.695

4.  Efficient enhancement of lentiviral transduction efficiency in murine spermatogonial stem cells.

Authors:  Bang-Jin Kim; Ki-Jung Kim; Yong-Hee Kim; Yong-An Lee; Byung-Gak Kim; Chul Min Cho; Hye-Ryeon Kang; Chul Geun Kim; Buom-Yong Ryu
Journal:  Mol Cells       Date:  2012-04-17       Impact factor: 5.034

5.  Changing viral tropism using immunoliposomes alters the stability of gene expression: implications for viral vector design.

Authors:  Peng H Tan; Shao-An Xue; Bin Wei; Angelika Holler; Ralf-Holger Voss; Andrew J T George
Journal:  Mol Med       Date:  2007 Mar-Apr       Impact factor: 6.354

Review 6.  Gene therapy for Fabry disease.

Authors:  C Siatskas; J A Medin
Journal:  J Inherit Metab Dis       Date:  2001       Impact factor: 4.982

Review 7.  Gene therapy for inherited retinal degeneration.

Authors:  R R Ali; M B Reichel; D M Hunt; S S Bhattacharya
Journal:  Br J Ophthalmol       Date:  1997-09       Impact factor: 4.638

8.  Cationic liposomes enhance the rate of transduction by a recombinant retroviral vector in vitro and in vivo.

Authors:  C D Porter; K V Lukacs; G Box; Y Takeuchi; M K Collins
Journal:  J Virol       Date:  1998-06       Impact factor: 5.103

9.  Impact of lentiviral vector-mediated transduction on the tightness of a polarized model of airway epithelium and effect of cationic polymer polyethylenimine.

Authors:  Stefano Castellani; Sante Di Gioia; Teresa Trotta; Angela Bruna Maffione; Massimo Conese
Journal:  J Biomed Biotechnol       Date:  2010-06-21

10.  Design of hybrid lipid/retroviral-like particle gene delivery vectors.

Authors:  Rahul K Keswani; Ian M Pozdol; Daniel W Pack
Journal:  Mol Pharm       Date:  2013-03-26       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.